Citations

Institution: Mayo Clinic Clear

Showing 10 of 108083 citations.

The future and digital transformation of hypertension care: results from the ESH CARE app trial
Ortega-Aviles, Laura M., Medina‐Inojosa, Betsy J. , Medina-Inojosa, José R , Ortega-Aviles, L M , Medina‐Inojosa, José R.

European Journal of Preventive Cardiology | September 4, 2025 | Volume: 33 | Issue: 7 | Pages: 1172-1173

10.1093/eurjpc/zwaf572 | PMID 40911523 Get It

Limited added utility of urine ethyl glucuronide compared to blood phosphatidylethanol in a predominantly transplant population
Snozek, Christine L.H. , Jannetto, Paul J. , Langman, Loralie J., Kinard, Theresa N.

Journal of Analytical Toxicology | September 4, 2025 | Volume: 50 | Issue: 1 | Pages: No page available

10.1093/jat/bkaf084 | PMID 40910927 Get It

Abstract Background Alcohol biomarkers including ethyl glucuronide (EtG) and phosphatidylethanol (PEth) are ordered frequently in clinical and forensic settings including solid organ transplantation. PEth provides a long detection window but can be insensitive to light drinking. In contrast, EtG and ethyl sulfate (EtS) can be elevated after light alcohol consumption and might complement PEth testing. Methods Urine EtG/EtS and whole blood PEth results were evaluated from all clinically-ordered testing between 2014 and 2024. PEth and EtG/EtS confirmation were performed by liquid chromatography tandem mass spectrometry at two reference laboratories, using cutoffs: Lab A, PEth 20 ng/ml, EtG and EtS 500 and 250 ng/ml; Lab B, PEth 10 ng/ml, EtG and EtS 250 and 100 ng/ml. Only Lab B performed EtG screening by immunoassay, using a 500 ng/ml cutoff. Results Phosphatidylethanol was positive in 1269 (15.6%) of 8131 samples, compared to 769 (6.7%) confirmed EtG/EtS positives from 11 555 samples. EtG screening (n = 9668) was positive in 743 (7.7%) samples, of which 30 (4.0%) confirmed negative (false positives); the screen was indeterminate in 267 (2.8%) samples, 66 of which confirmed positive and 172 negative. Of 3132 paired PEth and EtG samples, 2887 (92.2%) were concordant, 224 (7.2%) were PEth-positive, and 21 (0.7%) were EtG-positive. PEth was significantly more sensitive in paired samples (P < .001), even after accounting for potential confounders such as transfusion. Limiting testing to PEth would have correctly identified alcohol consumption in 331 of 373 (88.7%) instances versus EtG/EtS in 149 (39.9%), and reduced charges by >$720 000 USD. Discussion Phosphatidylethanol outperformed EtG/EtS in detecting alcohol consumption in a predominantly abstinent transplant population. Compared to PEth, EtG/EtS had lower overall positivity and poorer sensitivity in paired samples; additionally, EtG screening demonstrated false positives and indeterminate results. EtG testing provided little added value beyond PEth in this population, and did not warrant the increased cost of performing both tests.
Right Atrial Thrombus Complicating LVAD Candidacy: A Clinical Case Study
Alak, Çetin , Desai, Aarti , El‐Sabbagh, Abdallah, Yip, Daniel , Goswami, Rohan , Yip, Daniel S , Goswami, Rohan M , Desai, Aarti

Journal of Clinical Medicine | September 4, 2025 | Volume: 14 | Issue: 17 | Pages: 6242

10.3390/jcm14176242 | PMID 40944002 Get It

Background: Right atrial thrombus (RAT), though rare, carries a high risk of pulmonary or systemic embolism and a 25–44% mortality rate. In LVAD candidates, coexisting RAT significantly complicates perioperative management due to their critical condition and high risk of decompensation during surgery. Percutaneous thrombectomy offers a less invasive, lower-risk alternative to open surgery, enabling faster recovery. Case Presentation: We present a case of a 76-year-old male with ischemic cardiomyopathy and heart failure secondary to Adriamycin chemotherapy with an ejection fraction (EF) of 26%, diabetes mellitus, and stage 3 chronic kidney disease, scheduled for left ventricular assist device (LVAD) implantation. Preoperative echocardiography revealed a large, multilobulated, mobile thrombus in the right atrium. Given the high surgical risk and thrombus mobility, percutaneous thrombectomy using the AngioVac system (Angiodynamics, Latham, NY, USA) was performed. The thrombus was successfully removed, and the patient was discharged on apixaban for long-term anticoagulation. Advanced medical therapy and transplant/durable LVAD evaluation were delayed by 35 days to allow for the stabilization of any postoperative effects. Conclusions: This case underscores the efficacy of percutaneous thrombectomy as a bridge to LVAD in high-risk patients, reducing thromboembolic complications and supporting safe LVAD implantation.
An Uncommon Cause of Angina
Majdalany, David , Blickenstaff, Elaina A. , Marcotte, François , Anderson, Jason , Majdalany, David S , Anderson, Jason H. , Anderson, Jason H., Blickenstaff, Elaina A.

Diagnostics | September 4, 2025 | Volume: 15 | Issue: 17 | Pages: 2241

10.3390/diagnostics15172241 | PMID 40941728 Get It

Coronary anomalies, although rare, should be considered when young patients present with angina. Clinical suspicion and multi-modality imaging including coronary angiography and tomographic imaging should be pursued for symptomatic patients such as the one we are presenting with anomalous right coronary artery from the pulmonary artery. She was promptly referred for surgical intervention with re-implantation of the right coronary artery onto the aorta.
Transforming Clinical Workflows with Spatial Reasoning AI: A Scoping Review of Real-Time Systems and Architectures
Xu, Beilei , Qian, Ray , Ryu, Alexander J. , Lee, Arnold, Jose, James, Ayanian, Shant , Ryu, Alexander J.

No container title available | September 4, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-7511758/v1 Get It

Abstract Background: Spatial Reasoning AI (SRAI) systems are reshaping clinical practice by enabling real-time interpretation of complex anatomical structures in medical imaging, surgery, and chronic disease management (Lin et al., 2023, Qiao et al., 2021; Song et al., 2024) . Unlike traditional AI approaches that rely on tabular or 2D data, SRAI models incorporate geometric priors, multimodal fusion, and 3D anatomical reasoning to support high-impact tasks such as volumetric segmentation, disease localization, and intraoperative guidance (Milletari et al., 2016; Hatamizadeh et al., 2022; Zhang et al., 2022) . Objective: This scoping review aimed to (1) characterize the emerging landscape of spatial reasoning models in healthcare, (2) evaluate their clinical performance across diagnostic and prognostic applications, and (3) identify architectural trends that underpin successful translation into practice. Methods: Following PRISMA guidelines, we systematically screened PubMed to identify studies that implemented spatially aware AI models with real-time or clinically validated outcomes (Page et al., 2021) . Data extraction captured model architecture, modality, anatomical scope, clinical application, and performance metrics. Results: We identified 124 eligible studies across the clinical domains of oncology, neurology, cardiology, orthopedic surgery, and infectious diseases (Nie et al., 2019; Hao et al., 2020; Tasken et al., 2023) . SRAI systems consistently outperformed conventional methods in segmentation, lesion classification, and risk stratification. (Lin et al., 2023; Qiao et al., 2021; Mahootiha et al., 2024) . A paradigm shift from task-specific CNNs to foundation models that reason across spatial structures has emerged, beginning with adaptations of generalist models such as MedSAM and MedCLIP for zero-shot segmentation and cross-modal retrieval, and NeRF-based reconstruction for anatomically faithful 3D modeling (Ma et al., 2024; Mildenhall et al., 2020; Radford et al., 2021). Beyond technical performance, randomized evidence shows that SRAI systems can improve workflow efficiency without compromising outcomes (Lang et al., 2023) . Conclusion: SRAI models hold promise for enhancing diagnostic accuracy, prognostic precision, and clinical efficiency across diverse applications. Their successful integration will depend on standardized evaluation metrics, robust validation, and interpretable outputs. As foundation models evolve to better encode spatial priors, SRAI is poised to become a cornerstone of personalized and procedural medicine.
A Tale of Two Diseases
Collazo–Clavell, Maria L.

New England Journal of Medicine | September 3, 2025 | Volume: 393 | Issue: 9 | Pages: 916-917

10.1056/nejme2510196 | PMID 40902168 Get It

Randomized Phase II Trial of Pazopanib Versus Placebo in Patients With Advanced Extrapancreatic Neuroendocrine Tumors (Alliance A021202)
Bergsland, Emily K. , Geyer, Susan, Asmis, Timothy R., Behr, Spencer C. , Kuebler, J. Philip , Kumthekar, Priya , Mazza, Gina L. , Maitland, Michael L. , Niedzwiecki, Donna , Nixon, Andrew B. , Schwartz, Lawrence H., Meyerhardt, Jeffrey A. , Schwartz, Lawrence H. , Mazza, Gina L , Strosberg, Jonathan R , Venook, Alan P , O'Reilly, Eileen M , Meyerhardt, Jeffrey A , Nixon, Andrew B , Niedzwiecki, Donna , Schwartz, Lawrence H , Kuebler, Philip , Strosberg, Jonathan , Venook, Alan P. , O’Reilly, Eileen M.

Journal of Clinical Oncology | September 3, 2025 | Volume: 43 | Issue: 29 | Pages: 3170-3183

10.1200/jco-24-02644 | PMID 40902132 Get It

PURPOSE Patients with advanced, well-differentiated extrapancreatic neuroendocrine tumors (epNETs) have limited systemic treatment options. Pazopanib, an oral multikinase inhibitor with activity against vascular endothelial growth factor receptor (VEGFR)-2 and -3, PDGFR-alpha and-beta, and c-Kit, was tested for efficacy in epNET. PATIENTS AND METHODS We conducted a multicenter, randomized, double-blind, phase II study of pazopanib (800 mg once daily) versus placebo in low- to intermediate-grade epNET with radiologic progressive disease (PD) within 12 months of study entry. Previous somatostatin analog (SSA) was required for midgut tumors, and concurrent SSA was allowed. The primary end point was progression-free survival (PFS) by blinded independent central review. Unblinding and crossover were allowed if PD was confirmed by central review. RESULTS One hundred seventy-one patients (97 pazopanib and 74 placebo) were randomly assigned between September 2013 and October 2015. The majority had a midgut primary site (75%) and previous SSA treatment (93%). About half (49%) of the patients had functional tumors. The median follow-up was 61 months (95% CI, 60 to 63). Median PFS was 11.8 versus 7.6 months in pazopanib versus placebo, respectively (hazard ratio, 0.54 [95% CI, 0.37 to 0.79]; P < .001); 49 placebo patients crossed over to pazopanib. There was no significant difference in overall survival between the treatment arms. Rates of grade 3 or greater adverse events (regardless of attribution) were higher in pazopanib versus placebo (84% v 47%; P < .001), as were grade 5 death events (8% v 0%, P = .017). CONCLUSION Pazopanib compared with placebo significantly improves PFS in patients with progressive epNET, confirming that the VEGF signaling pathway is a valid target for therapy in epNET. However, after integrating the associated risks relative to the benefits, further development of pazopanib in this clinical context is not planned.
Identification of 4 autophagy-related genetic variants as risk factors for chronic lymphocytic leukemia
Cabrera-Serrano, Antonio José , Rodríguez‐Sevilla, Juan José , Reyes‐Zurita, Fernando J. , Collado, Rosa , Puiggros, Anna, Cornejo-Calvo, Elena , Horst, Rob ter , Benavente, Yolanda , Jerez, Andrés , Ramos‐Campoy, Sílvia , González‐Olmedo, Carmen , Jannus, Fatin , Marcos‐Gragera, Rafael , Carretero-Fernández, María, Sampaio‐Marques, Belém , Gámez, Irene, García‐Álvarez, María , Camp, Nicola J. , Kamaso, Joanna, Pérez, Eva María, Alcoceba, Miguel , Campa, Daniele , Sanjosé, Sílvia de , Netea, Mihai G. , McKay, James, Casabonne, Delphine , Berndt, Sonja I. , Sáinz, Juan , Rodríguez-Sevilla, Juan José , Reyes-Zurita, Fernando Jesús , Collado, Rosa , Cornejo-Calvo, Elena , Ter Horst, Rob , Landi, Stefano , Espinet, Blanca , Maffei, Rossana , López-Nevot, Miguel Ángel , Ramos-Campoy, Silvia , Chen-Liang, Tzu-Hua , Jannus, Fatin , Marcos-Gragera, Rafael , Carretero-Fernández, María , Sampaio-Marques, Belém , Camp, Nicola J , Dierssen-Sotos, Trinidad , Kamaso, Joanna , Li, Yang , Marasca, Roberto , Ludovico, Paula , Canzian, Federico , Casabonne, Delphine , Berndt, Sonja I , Slager, Susan L , Sainz, Juan , Alcoceba, Miguel , Sánchez‐Maldonado, José Manuel , Puiggros, Anna , García-Martín, Paloma, Landi, Stefano , Espinet, Blanca , Maffei, Rossana , López‐Nevot, Miguel Ángel , Moreno, Vı́ctor , Dierssen‐Sotos, Trinidad , Norman, Aaron D. , Luppi, Mario , Li, Yang , Marasca, Roberto , Ludovico, Paula , Clay‐Gilmour, Alyssa , Canzian, Federico , Ibáñez, Mariam , McKay, James , Slager, Susan L. , Netea, M. G.

Blood Advances | September 3, 2025 | Volume: 9 | Issue: 23 | Pages: 6076-6089

10.1182/bloodadvances.2025017345 | PMID 40902075 Get It

Abstract We investigated the influence of 55 583 autophagy-related single-nucleotide polymorphisms (SNPs) on chronic lymphocytic leukemia (CLL) risk across 4 independent populations comprising 5472 CLL cases and 726 465 controls. We also examined their impact on overall survival (OS), time to first treatment (TTFT), autophagy flux, and immune responses. A meta-analysis of the 4 populations identified, to our knowledge, for the first time, significant associations between CDKN2A (rs3731204) and BCL2 (rs4940571, rs12457371, and rs1026825) SNPs and CLL risk, with CDKN2A showing the strongest association (P = 1.57 × 10−12). We also validated previously reported associations for FAS, BCL2, and BAK1 SNPs with CLL risk (P = 4.73 × 10−21 to 3.39 × 10−9). The CDKN2Ars3731204 and FASrs1926194 SNPs associated with increased CDKN2A and ACTA2 messenger RNA expression levels in the whole blood and/or lymphocytes (P = 5.1 × 10−7, P = 1.58 × 10−21, and P = 7.8 × 10−41), although no significant effect on autophagy flux was observed. However, associations were found between CDKN2A, BCL2, and FAS SNPs and various T-cell subsets, cytokine production, and circulating concentrations of interferon gamma, tumor necrosis factor–related apoptosis-inducing ligand, CD40, chemokine ligand 20, and interleukin-2 receptor subunit β proteins (P ≤ .005). No significant association was detected between autophagy variants and OS or TTFT, suggesting that these variants drive disease initiation rather than progression. In conclusion, this study identified 4 novel associations for CLL and provided insights into the biological pathways that influence CLL development.
Transforming Care of Duchene Muscular Dystrophy in Low-Resource Setting Through Community-Led Initiatives
Humayun, Muhammad Abdullah, Zaheer, Amna , Akbar, Anum

Journal of Clinical Neuromuscular Disease | September 3, 2025 | Volume: 27 | Issue: 1 | Pages: 22-24

10.1097/cnd.0000000000000533 | PMID 40901872 Get It